Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 9/20 | 0.45 |
| ▸ | CTSS | P25774 | 5/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484138 | 0.86 | CA1 (0.53) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL28912472 | 0.84 | CA1 (0.52) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL10669928 | 0.84 | CA1 (0.52) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL10652 | 0.81 | CA1 (0.57) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL24069882 | 0.81 | CA1 (0.57) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL19441856 | 0.81 | CA1 (0.49) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL23849248 | 0.80 | CA1 (0.52) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL1689249 | 0.80 | CA1 (0.52) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL23607312 | 0.80 | CA1 (0.52) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL895110 | 0.79 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438448-B1 | MASS LABELS, KIT AND METHOD FOR MASS SPECTROMETRY ANALYSIS OF KETONE AND ALDEHYDE ANALYTES | DH TECHNOLOGIES DEV PTE LTD (SG) | 2020-05-20 | — | — | EP | disclosed |
| US-10094809-B2 | Specific analysis of ketone and aldehyde analytes using reagent compounds, labeling strategies, and mass spectrometry workflow | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2018-10-09 | — | — | US | disclosed |
| US-20170115258-A1 | SPECIFIC ANALYSIS OF KETONE AND ALDEHYDE ANALYTES USING REAGENT COMPOUNDS, LABELING STRATEGIES, AND MASS SPECTROMETRY WORKFLOW | DH TECHNOLOGIES DEV PTE LTD (SG) | 2017-04-27 | — | — | US | disclosed |
| US-9500622-B2 | Specific analysis of ketone and aldehyde analytes using reagent compounds, labeling strategies, and mass spectrometry workflow | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2016-11-22 | — | — | US | disclosed |
| US-20140004616-A1 | SPECIFIC ANALYSIS OF KETONE AND ALDEHYDE ANALYTES USING REAGENT COMPOUNDS, LABELING STRATEGIES, AND MASS SPECTROMETRY WORKFLOW | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2014-01-02 | — | — | US | disclosed |
| US-20110003395-A1 | SPECIFIC ANALYSIS OF ANALYTES USING REAGENT COMPOUNDS, LABELING STRATEGIES, AND MASS SPECTROMETRY WORKFLOW | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2011-01-06 | — | — | US | disclosed |
| WO-2010141075-A1 | SPECIFIC ANALYSIS OF KETONE AND ALDEHYDE ANALYTES USING REAGENT COMPOUNDS LABELING STRATEGIES, AND MASS SPECTROMETRY WORKFLOW | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003395-A1 | SPECIFIC ANALYSIS OF ANALYTES USING REAGENT COMPOUNDS, LABELING STRATEGIES, AND MASS SPECTROMETRY WORKFLOW | HSD17B7, HSD17B13, HSD11B1 | CA1 2175/4885CA2 4559/4885CA7 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.